Cartesian Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cartesian Therapeutics generated cash of -$51,161,000, which is less than the previous year. Cash used in financing activities reached the amount of -$13,145,000 last year. Net change in cash is therefore -$29,750,000.
Cash Flow
| 2015 | -22.46M | -4.67M | 43.90M |
|---|---|---|---|
| 2017 | -52.03M | -2.09M | 66.02M |
| 2019 | -51.43M | 229K | 105.04M |
| 2020 | 34.88M | -741K | 14.43M |
| 2021 | -60.38M | -17.14M | 52.89M |
| 2022 | -31.63M | -15.00M | 39.21M |
| 2023 | -51.16M | 34.60M | -13.14M |
RNAC Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2015 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 108.03M | 115.43M | 140.06M | 91.55M | 37.40M | 58.73M | 15.70M |
Operating activities | |||||||
Net income | -219.71M | 35.37M | -25.68M | -68.87M | -55.35M | -65.32M | -25.17M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.55M | 1.28M | 1.25M | 734K | 2.02M | 750K | 1.04M |
Stock-based compensation expense | 22.52M | 11.19M | 7.72M | 5.42M | 0 | 0 | 0 |
| Deferred income tax benefit | 22.52M | 11.19M | 7.72M | 5.42M | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 907K | 3.31M | -2.69M | -2.22M | -5M | 152K | -153K |
Inventories | 0 | 920K | 211K | -7.17M | 0 | 0 | 0 |
Accounts payable | 2.83M | 92K | -219K | -57K | -600K | -2.32M | 667K |
Cash generated by operating activities | -51.16M | -31.63M | -60.38M | 34.88M | -51.43M | -52.03M | -22.46M |
Investing activities | |||||||
Purchases Of Investments | 0 | -33.50M | -32.45M | 0 | -18.18M | -61.52M | 0 |
Investments In Property Plant And Equipment | -206K | -1.20M | -1.08M | -815K | -47K | -733K | -1.16M |
Acquisitions Net | 6.56M | 0 | 0 | 74K | 122K | 4K | 0 |
Cash generated by investing activities | 34.60M | -15.00M | -17.14M | -741K | 229K | -2.09M | -4.67M |
Financing activities | |||||||
Common Stock Issued | 0 | 38.98M | 51.95M | 12.37M | 37.66M | 57.11M | 109K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -6.16M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -27.45M | 0 | 0 | -19.31M | -2.8M | 8.02M | 11.43M |
Cash used in financing activities | -13.14M | 39.21M | 52.89M | 14.43M | 105.04M | 66.02M | 43.90M |
Net Change In Cash | -29.75M | -7.39M | -24.62M | 48.51M | 52.76M | 11.96M | 16.76M |
Cash at end of period | 78.28M | 108.03M | 115.43M | 140.06M | 90.17M | 70.69M | 32.47M |